ライフサイエンスコーパス: surface antigen

1 as primarily within the G protein, the major surface antigen.

2 bo group; no patient had loss of hepatitis B surface antigen.

3 (0.7%) in the FTC/TDF group lost hepatitis B surface antigen.

4 ation mostly within the G protein, the major surface antigen.

5 r surface and post modified with hepatitis B surface antigen.

6 antigen receptors (CARs) for a specific cell-surface antigen.

7 opulation for which there is a characterised surface antigen.

8 an unconjugated mAbs targeting the same cell surface antigen.

9 hs from screening in carriers of hepatitis B surface antigen.

10 till far from achieving seroclearance of HBV surface antigen.

11 as diagnostic systems for various tumors and surface antigens.

12 loss of immune tolerance to nuclear and cell surface antigens.

13 romote viral release and is one of the major surface antigens.

14 pulsing on DC phenotypic expression of cell-surface antigens.

15 itation of adaptive immune responses against surface antigens.

16 ophage contents, showed differences in major surface antigens.

17 arby genes also encoding immunodominant cell surface antigens.

18 s, each presenting a different repertoire of surface antigens.

19 igger the expression of ICAM-1 and CD40 cell surface antigens.

20 ephalitis with antibodies targeting neuronal surface antigens.

21 he immune response directed toward invariant surface antigens.

22 odel of multivalent antibody binding to cell surface antigens.

23 Variant surface antigen 2-CSA (VAR2CSA), a Plasmodium falciparum

24 Using coli surface antigen 20 (CS20) fimbriae as a model ETEC colon

25 in plasma and loss of detectable hepatitis B surface antigen after cessation of therapy.

26 /NTCP cells secreted very little hepatitis B surface antigen after infection with cell culture-derive

27 rri of complex target molecules such as cell surface antigens, allergens, and food contaminants.

28 ALL leukemic cells express several surface antigens amenable to target therapies, including

29 k children at 1 year of age with hepatitis B surface antigen and anti-hepatitis B to identify those w

30 Another major surface antigen and autotransporter, rOmpB, exhibits a d

31 yte expansion, and expression of hepatitis B surface antigen and core antigen in liver tissues from 2

32 Serum levels of HBV surface antigen and HBV e antigen, and numbers of HBV an

33 Strong liver expression of hepatitis B surface antigen and hepatitis B core antigen was detecte

34 B viral infection by testing for hepatitis B surface antigen and the antibody to hepatitis B core ant

35 onal antibodies targeting neuroblastoma cell surface antigens and attached cells were removed using s

36 een the production of antibodies against WHV surface antigens and parameters of WHV infection appears

37 idase (NA) is one of the two major influenza surface antigens and the main influenza drug target.

38 in genes responding to rsp, which regulates surface antigens and toxin production; agr, which regula

39 puts: the simultaneous expression of a (cell surface) antigen and secreted enzyme to generate functio

40 21,419 veterans with a positive hepatitis B surface antigen, and 97% of patients had alanine aminotr

41 y to gamma-sarcoglycan, a cardiomyocyte cell surface antigen, and mixed with freshly isolated neonata

42 o rapidly reduce serum HBV DNA and serum HBV surface antigen, and they promote the elimination of hep

43 bacco smoking, alcohol drinking, hepatitis B surface antigen, and/or anti-hepatitis C virus positivit

44 rent AMA1 and MSP2 alleles of merozoites, IE surface antigens, and antibody functional activities wer

45 nal, recognizing both intracellular and cell surface antigens, and HSP60 was identified as one common

46 eropositive for both antibody to hepatitis B surface antigen (anti-HBs) and anti-HBc (13 of 233 [5.6%

47 ave reported loss of antibody to hepatitis B surface antigen (anti-HBs) in a high proportion of perso

48 detection of antibodies against hepatitis B surface antigen (anti-HBs) in clinical serum samples usi

49 sons were tested for antibody to hepatitis B surface antigen (anti-HBs) levels 30 years after receivi

50 es about whether the antibody to hepatitis B surface antigen (anti-HBs) protects against reactivation

51 ance with or without antibody to hepatitis B surface antigen (anti-HBs) seroconversion.

52 rent) infection; and antibody to hepatitis B surface antigen (anti-HBs), indicative of immunity from

53 of antibody against hepatitis B virus (HBV) surface antigen (anti-HBs), is undetermined.

54 luding high levels of antibodies against HBV surface antigen (anti-HBs).

55 any of HBV serological markers (hepatitis B surface antigen, anti-hepatitis B core antibodies, or HB

56 alanine aminotransferase, serum hepatitis B surface antigen, anti-hepatitis C virus antibody, and di

57 alanine aminotransferase, serum hepatitis B surface antigen, anti-hepatitis C virus positivity, and

58 e-induced HBV immunity (antibody against HBV surface antigen; anti-HBs) in U.S. Hispanics/Latinos and

59 ver half (52.9%) had antibody to hepatitis B surface antigen antibody levels of <10 mIU/mL and there

60 ice 2: Clinicians should screen (hepatitis B surface antigen, antibody to hepatitis B core antigen, a

61 By targeting internalizing cell surface antigens, antibody-siRNA complexes provide a pos

62 Immunodominant surface antigen B (IsaB) is a virulence factor that help

63 due to shared expression of most targetable surface antigens between normal and malignant T cells, p

64 s that recognized senescence-associated cell-surface antigens by FACS analysis and a newly developed

65 and pathogen is alterations in expression of surface antigens by simple sequence repeat (SSR)-mediate

66 rial lipooligosaccharide (LOS), a major cell-surface antigen, can be correlated with inflammatory pot

67 efficiencies and expression of putative CSC surface antigens (CD133 and CD44) were also increased.

68 These cells express the surface antigen CD15/SSEA-1 and have elevated levels of

69 t with high O/C potential and, further, that surface antigen CD166 is modulated during the O/C matura

70 maturation protein-1 (BLIMP-1), and the cell surface antigens CD38 and CD138/Syndecan-1.

71 ic syndromes and the discovery of novel cell surface antigen central nervous system autoimmune syndro

72 (RR = 2.1, 95% CI 1.4-3.3), and hepatitis B surface antigen clearance (RR = 5.8, 95% CI 1.1-31.5).

73 R = 1.4, 95% CI 1.1-1.8) but not hepatitis B surface antigen clearance or seroconversion.

74 A vaccine with four surface antigens (ClfA, FnBPB, SdrD, and SpAKKAA), which

75 antimicrobial peptides (NCR), and a malaria surface antigen domain of apical membrane antigen AMA-1.

76 ze properties of the CTCs themselves such as surface antigens (e.g., epithelial cell adhesion molecul

77 against a cocktail containing bacterial cell-surface antigens enhanced disease severity as tested by

78 specific antibodies after removal of the HBV surface antigen envelope demonstrated the association of

79 us (HBV) coinfection to provide HDV with HBV surface antigen envelope proteins.

80 he C-terminal addition of a GPI-anchor (from surface antigen EtSAG1) mCherry was expressed on the spo

81 tions, is frequently accomplished using cell surface antigens expressed by the cells of interest.

82 f immunoglobulin G antibodies targeting cell surface antigens expressed in multiple cGVHD affected ti

83 abel free using the specific binding of cell surface antigens expressed on the surface of cancer cell

84 ozoites did not decline and antibodies to IE surface antigens expressing virulent phenotypes were muc

85 cells into clinical applications, their cell surface antigen expression and its chemical structural c

86 copy were used to investigate alterations in surface antigen expression and morphology following path

87 We used flow cytometry to characterize cell surface antigen expression on human testicular cells and

88 The surface antigen expression profiles of pretherapy and po

89 tamination by exploiting differences in cell surface antigen expression.

90 The OmpD surface antigen extraction was done from Salmonella typh

91 Greater numbers of the variant surface antigen families RIFIN, STEVOR, and PfMC-2TM wer

92 Furthermore, 2 major surface antigen families, PfEMP1 and STEVOR, are no long

93 deep vascular beds, mediated by the variant surface antigen family PfEMP1 binding endothelial recept

94 , a member of the P. falciparum EMP1 variant surface antigen family, is the leading candidate for a p

95 target essentially any tumor-associated cell-surface antigen for which a monoclonal antibody can be m

96 eceptors that redirect polyclonal T cells to surface antigens for subsequent tumor elimination.

97 B core antigen, and antibody to hepatitis B surface antigen) for HBV in high-risk persons, including

98 ribed by RNA polymerase I with the procyclin surface antigen genes expressed on trypanosome insect fo

99 ) site at amino acid residue 197 (N7) on the surface antigen gp120 of HIV-1 increases neutralization

100 (CD4i) transition state epitopes in the HIV surface antigen, gp120, while not exposed on free partic

101 antibody specific for the CD20 B-lymphocyte surface antigen, has been increasingly adopted as a firs

102 Many surface antigens have been previously used to identify h

103 to significantly more decline in hepatitis B surface antigen, HBeAg, and HBV DNA (all P < 0.001).

104 us (HBV) DNA (</=2000 IU/mL) and hepatitis B surface antigen (HBsAg) (<1000 IU/mL) have been shown to

105 for prevalent diabetes comparing hepatitis B surface antigen (HBsAg) (+) to HBsAg (-) participants wa

106 is strategy, we investigated the hepatitis B surface antigen (HBsAg) and alpha-fetoprotein (AFP) with

107 after July 1987 were assayed for hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HB

108 to report seroprevalence of both hepatitis B surface antigen (HBsAg) and antibodies to HCV (anti-HCV)

109 Serologic HBV markers, including hepatitis B surface antigen (HBsAg) and e antigen (HBeAg), were test

110 Screening should include both hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (a

111 ed by on-treatment monitoring of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA.

112 Therefore, the interaction of hepatitis B surface antigen (HBsAg) and KCs, and possible functional

113 ired toll-like receptor signaling by the HBV surface antigen (HBsAg) attenuates immune responses to f

114 Hepatitis B virus surface antigen (HBsAg) became negative in six PEG-IFNa-

115 e antigen (HBeAg)-seropositive, hepatitis B surface antigen (HBsAg) carrier children, who were follo

116 k factors were cohabitation with hepatitis B surface antigen (HBsAg) carriers, intravenous drug use,

117 ls in the process of hepatitis B virus (HBV) surface antigen (HBsAg) clearance and whether their phen

118 reatment response was defined as hepatitis B surface antigen (HBsAg) clearance with or without antibo

119 Point-of-care tests for hepatitis B surface antigen (HBsAg) could be an ideal tool for a lar

120 34 RA patients who had available hepatitis B surface antigen (HBsAg) data, 123 patients positive for

121 hepatitis delta virus (HDV) and hepatitis B surface antigen (HBsAg) during interferon-alpha therapy.

122 les are formed from a single CSP-hepatitis B surface antigen (HBsAg) fusion protein, and this leads t

123 of infection with a hepatitis B virus (HBV) surface antigen (HBsAg) gene mutant (hereafter, "HBsAg-m

124 Here, we investigated hepatitis B surface antigen (HBsAg) genetic features underlying this

125 sispecies with reverse transcriptase and HBV surface antigen (HBsAg) heterogeneity in patients with a

126 pecific seroclearance pattern of hepatitis B surface antigen (HBsAg) in chronic hepatitis B virus (HB

127 epG2 cells, although very little hepatitis B surface antigen (HBsAg) is produced.

128 The serum hepatitis B virus (HBV) surface antigen (HBsAg) level can predict hepatocellular

129 y investigated the role of serum hepatitis B surface antigen (HBsAg) levels and established models fo

130 HBV RNA, HBV DNA, and hepatitis B surface antigen (HBsAg) levels as well as presence of HB

131 epatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels during flares.

132 d clinical significance of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleosi

133 nts with low viral loads, higher hepatitis B surface antigen (HBsAg) levels have been shown to predic

134 The kinetics of hepatitis B surface antigen (HBsAg) levels preceding spontaneous HBs

135 Plasma HDV and HBV loads and HBV surface antigen (HBsAg) levels were determined for the H

136 active hepatitis, correlating with high HBV surface antigen (HBsAg) levels.

137 On-treatment levels of hepatitis B surface antigen (HBsAg) may predict response to peginter

138 core antibody (anti-HBc) without hepatitis B surface antigen (HBsAg) or hepatitis B surface antibody

139 infection until the clearance of hepatitis B surface antigen (HBsAg) or the development of chronic in

140 lasma level of HBV DNA with undetectable HBV surface antigen (HBsAg) outside the preseroconversion wi

141 lls, extracellular vesicles, and hepatitis B surface antigen (HBsAg) particles of hepatoma cell lines

142 A total of 42 hepatitis B surface antigen (HBsAg) positive, human immunodeficiency

143 d NIM811) on HBV replication and hepatitis B surface antigen (HBsAg) production in cell lines.

144 ommunity-based screening using a hepatitis B surface antigen (HBsAg) rapid test and subsequent HBV an

145 Model fits show that hepatitis B surface antigen (HBsAg) remained stable after a short ph

146 the time of HBV reactivation and hepatitis B surface antigen (HBsAg) reverse seroconversion since che

147 s in western Gambia were offered hepatitis B surface antigen (HBsAg) screening via a point-of-care te

148 NPs) at HLA-DP and IL28B loci on hepatitis B surface antigen (HBsAg) seroclearance in chronic hepatit

149 monoinfected patients and a high hepatitis B surface antigen (HBsAg) seroclearance rate.

150 The cumulative rates of hepatitis B surface antigen (HBsAg) seroclearance were 90% and 95% a

151 Two cross-sectional surveys on HBV surface antigen (HBsAg) seroprevalence were conducted in

152 mans vaccinated with hepatitis B virus (HBV) surface antigen (HBsAg) sometimes develop humoral and ce

153 load, 7 had positive results on hepatitis B surface antigen (HBsAg) testing and had an undetectable

154 The 90-day hepatitis B surface antigen (HBsAg) testing rate was 28.1% in 15 357

155 Using quantitative maternal surface antigen (HBsAg) to predict HBV infection in infa

156 mal immunization of mice against hepatitis B surface antigen (HBsAg) using a novel real-time controll

157 The serum gradient of hepatitis B surface antigen (HBsAg) varies over time after cessation

158 At birth, hepatitis B surface antigen (HBsAg) was detected in 20% and 24% of n

159 Immunoglobulin G (IgG) and Hepatitis B surface Antigen (HBsAg) were quantitatively analyzed wit

160 reening for hepatitis B virus (HBV) DNA, HBV surface antigen (HBsAg), and antibodies to surface (anti

161 All were tested for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core an

162 9 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhancing the restoration of fu

163 okine measurements, quantitative hepatitis B surface antigen (HBsAg), HBeAg levels, HBV genotype, and

164 and hepatitis we identified all hepatitis B surface antigen (HBsAg), HBV DNA, and alanine aminotrans

165 ed on age-specific prevalence of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg),

166 ative of previous HBV infection; hepatitis B surface antigen (HBsAg), indicative of chronic (current)

167 an immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), prevalent hepatic decompensatio

168 We focused our study on the HBV surface antigen (HBsAg), which is present in microgram q

169 CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss after long-

170 lticenter trial and enrolled 118 hepatitis B surface antigen (HBsAg)- and hepatitis B e antigen-posit

171 HIV-1-infected and HBV surface antigen (HBsAg)-negative pregnant women were tes

172 ection (OBI), serum samples from hepatitis B surface antigen (HBsAg)-negative subjects <18 years enro

173 is B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative, antibody to hepatitis

174 lticenter, cohort study of 2,562 hepatitis B surface antigen (HBsAg)-positive individuals was conduct

175 This analysis included hepatitis B surface antigen (HBsAg)-seropositive and anti-HCV-serone

176 ifier for determination of hepatitis B virus surface antigen (HBsAg).

177 cDNA, RNA, and expression of the hepatitis B surface antigen (HBsAg).

178 pregnant women are screened for hepatitis B surface antigen (HBsAg).

179 s with "resolved" HBV infection (hepatitis B surface antigen [HBsAg] negative and hepatitis B core an

180 ntreated (25) or NUC treated (36 hepatitis B surface antigen [HBsAg](+) and 10 HBsAg(-)/hepatitis B s

181 quest for a serological profile (hepatitis B surface antigen [HBsAg], anti-HBc, and anti-HBs) in pati

182 ; anti-HBc), active HBV infection (serum HBV surface antigen; HBsAg), and vaccine-induced HBV immunit

183 HBV surface antigens (HBsAgs) can be produced either by HBV

184 infection as a positive test for hepatitis B surface antigen, HBV DNA, or hepatitis B e antigen.

185 coding for proteins that are homologs of the surface antigens, hemagglutinin (HA) and neuraminidase (

186 DNA serum levels or antibody to hepatitis B surface antigen/hepatitis B surface antigen seroreversio

187 Quantitative hepatitis B surface antigen in addition to other clinical data may p

188 were also able to detect antibodies to these surface antigens in C abortus-infected women who had und

189 ymphopoiesis-related genes and lymphoid cell-surface antigens in LEF1high patients.

190 ttractive vaccine candidates as they present surface antigens in their natural context.

191 Cell surface antigens, in addition to HLA, may serve as the s

192 ic antibodies of different valencies to cell surface antigens including MET and EGF receptor, we have

193 both ETEC architecture and the expression of surface antigens, including a novel highly conserved adh

194 za hemagglutinin (HA) and neuraminidase (NA) surface antigens increase in the weeks after infection o

195 gest that vaccination against bacterial cell-surface antigens increases disease severity, but vaccina

196 However, surface antigen intensities differed, with significantly

197 e kinase such as orphan receptor 1 (Ror1), a surface antigen, is a member of the RTK family of Ror, w

198 is manifested by the expression of the cell surface antigen known as epithelial cell adhesion molecu

199 drug use, HCV RNA levels, hepatitis B virus surface antigen level, body mass index, and (for those w

200 HBV functional cure is sustained hepatitis B surface antigen loss and anti-HBs gain, with normalizati

201 The weighted probability of hepatitis B surface antigen loss was 2.0%.

202 ates of HBeAg seroconversion and hepatitis B surface antigen loss were low.

203 IV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or

204 IV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or

205 erent forms including overexpressed proteins/surface antigens, metabolites, miRNA, and the entire cel

206 iving donors and estimated all possible cell surface antigens mismatches for a given donor/recipient

207 nfected sheep developed mainly antibodies to surface antigens (MOMP, MIP, Pmp13G), all of which did n

208 d on the induction of antibodies to parasite surface antigens, most of which are highly polymorphic.

209 atients with resolved infection (hepatitis B surface antigen negative) receiving chemotherapy for hem

210 ncephalitis with antibodies against neuronal surface antigens (NSA-abs) may present with similar clin

211 scribing genetic redirection of T cells to a surface antigen of choice.

212 of circumsporozoite protein (CSP), the major surface antigen of Plasmodium falciparum (Pf) sporozoite

213 ecifically proposed in relation to the major surface antigen of the blood stage, known as PfEMP1 and

214 expression of distinct variants of the major surface antigen of the blood stages known as Pf EMP1 enc

215 Levels of IgG to variant surface antigens of infected erythrocytes (IEs) and mero

216 d structural and biochemical analysis of the surface antigens of the virus.

217 A specific surface antigen, OmpD has been reported first time as a

218 sing F(ab')2 fragments against a unique cell surface antigen on ACT cells (Thy1.1) or an engineered i

219 nAPN1 is a lead TBV candidate that targets a surface antigen on the midgut of the obligate vector of

220 lyfish-derived allergen showed expression of surface antigens on basophils increased in a concentrati

221 xins (antibody-toxin fusion proteins) target surface antigens on cancer cells and kill these cells vi

222 r-to-year variation in immune recognition of surface antigens on CGS parasite-infected erythrocytes.

223 unknown whether autoantibodies against cell-surface antigens on human RPCs exist in DR patients, whe

224 1b, if they tested positive for hepatitis B surface antigen or anti-HIV antibody at screening, or if

225 ncorporation of a spacer-into the mesothelin surface antigen or the cancer drug itself-converted SS-T

226 ; 95% CI: 1.09-1.40; P = 0.001), hepatitis B surface antigen, or anti-hepatitis C virus positivity (O

227 jects with positive serology for hepatitis B surface antigen (P for trend = 0.02).

228 t form of the relatively conserved merozoite surface antigen, PfRH5.

229 culating autoantibodies against the podocyte surface antigens phospholipase A2 receptor 1 (PLA2R1) an

230 Variant surface antigens play an important role in Plasmodium fa

231 novo HBV: two recipients became hepatitis B surface antigen positive at 70 and 23 months and three e

232 ified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we described LSM

233 ntibody positive, 85 (7.4%) were hepatitis B surface antigen positive, and 17 (1.5%) were anti-HDV po

234 tibody positive, and 9.0% (5.1-13.2) are HBV surface antigen positive; there is substantial geographi

235 ally exclusive pattern was found between HBV surface antigen-positive (HBsA-positive) and HBV DNA- an

236 RT was significantly impaired in hepatitis B surface antigen-positive patients and in those with anti

237 association became stronger for hepatitis B surface antigen-positive persons who also had low serum

238 eening; its application to the Mongolian HBV surface antigen-positive population reveals an apparent

239 Those who are found to be hepatitis B surface antigen-positive should start appropriate antivi

240 per week (IRR, 1.68, P < .001), hepatitis B surface antigen positivity (IRR, 1.68, P < .001), syphil

241 unodeficiency virus coinfection, hepatitis B surface antigen positivity, cirrhosis, and HCC at baseli

242 th human immunodeficiency virus, hepatitis B surface antigen positivity, hepatocellular carcinoma, or

243 bioavailability in DCs without altering cell-surface antigens, potentially making it a more potent th

244 ease, testing positive for hepatitis B virus surface antigen, pregnancy, creatinine clearance less th

245 that these inhibitors induce increased cell-surface antigen presentation of transfected and endogeno

246 anoparticles by lymphoma cells with distinct surface antigens pretreated with different bispecific st

247 that a virus containing a hemagglutinin (HA) surface antigen previously unseen by a majority of the p

248 sed a combination of differentiation assays, surface antigen profiling, and global gene expression an

249 hematically predicted that a highly variable surface antigen prolongs bacterial infection sufficientl

250 olecular link between the triggering of cell-surface antigen receptors and nuclear factor kappaB acti

251 ay analyses show that FUT8 globally modifies surface antigens, receptors, and adhesion molecules and

252 cells (OPCs) that are positive for the cell surface antigen recognized by the O4 antibody (O4(+)) ap

253 imated overall seroprevalence of hepatitis B surface antigen remains high at 6.1% (95% uncertainty in

254 with CPD-MAGE-A3 did not alter specific cell-surface antigens required for T-cell activation.

255 O-Glycosylation of CD43, a cell surface antigen rich in O-glycans, was drastically reduc

256 A major surface antigen, rickettsial outer membrane protein A (r

257 Monoclonal antibodies target these leukemic surface antigens selectively and minimize off-target tox

258 chemokine-receptor signaling, or that target surface antigens selectively expressed on CLL cells, pro

259 The cumulative rate of hepatitis B surface antigen seroclearance at 1, 5, and 10 years was

260 dence rates of HBV infection and hepatitis B surface antigen seroclearance were estimated after takin

261 To achieve functional cure (ie, HBV surface antigen seroclearance) and complete cure (ie, er

262 ronic carriers, and the rates of hepatitis B surface antigen seroclearance.

263 Patients with positive anti-hepatitis B surface antigen serology were excluded.

264 Eighty percent of them were hepatitis B surface antigen seropositive.

265 duced MTCT, as defined by infant hepatitis B surface antigen seropositivity (risk ratio = 0.3, 95% co

266 y to hepatitis B surface antigen/hepatitis B surface antigen seroreversion.

267 To identify disease state-specific surface antigen signatures, we combined fluorescent cell

268 gets such as cancer cells with other special surface antigens, significant biological small molecules

269 eukin 10, or interleukin 6 production by HBV surface antigen-specific T cells.

270 the high cancer-specific expression of cell surface antigens such as mesothelin, which is overexpres

271 ed proteins, primarily consisting of variant surface antigens such as P. falciparum erythrocyte membr

272 t VAR2CSA, the Plasmodium falciparum variant surface antigen that binds placental chondroitin sulfate

273 odies, each corresponding to a specific cell-surface antigen, that have been functionalized in a sing

274 host's immune attack by expressing its major surface antigen, the Variant Surface Glycoprotein (VSG),

275 n through vaccination against bacterial cell-surface antigens; thus far all have failed.

276 ogy has been the identification of conserved surface antigens to formulate a broadly protective vacci

277 mice, and in mice that carried a hepatitis B surface antigen transgene-this to model the multiplicati

278 Oncogenic surface antigen truncation mutations were detected in en

279 and the absence of hematopoietic or myeloid surface antigens; (v) self-renewal potential displayed b

280 anosomiasis and regularly switches its major surface antigen variant surface glycoprotein (VSG) to ev

281 of the parasite-derived variant erythrocyte surface antigen (VESA) expressed on the infected red blo

282 ncreases in cells, the stability of the cell surface antigen VlsE, which presumably did not evolve fo

283 antibodies to Plasmodium falciparum variant surface antigens (VSA) and antibodies that opsonise infe

284 nancy-specific Plasmodium falciparum variant surface antigens (VSA) and concentrations of cytokines T

285 anosomiasis and regularly switches its major surface antigen, VSG, in the bloodstream of its mammalia

286 anosomiasis and regularly switches its major surface antigen, VSG, thereby evading the host's immune

287 ne response by regularly switching its major surface antigen, VSG, which is expressed exclusively fro

288 Antibody to hepatitis B surface antigen was tested 1 month after the third vacci

289 rain immunohistochemistry optimized for cell-surface antigens was performed.

290 alciparum EMP-1 (PfEMP-1) is a major variant surface antigen, we used var Ups quantitative reverse tr

291 Neuronal surface antigens were detected in 6 of 346 patients (1.7

292 Cell viability and surface antigens were examined by 7-amino-actinomycin D

293 acy of the immune response to B. burgdorferi surface antigens were monitored via a superinfection mod

294 2], MSP-119, and the infected red blood cell surface antigens were not.

295 d cell-based assays with known neuronal cell-surface antigens were used.

296 e patients had antibodies against a neuronal surface antigen, which were also present in five additio

297 aracterized by sustained loss of hepatitis B surface antigen with or without hepatitis B surface anti

298 onoclonal antibodies (mAbs) that target cell surface antigens with restricted expression in pediatric

299 erapy is limited by the availability of cell surface antigens with sufficient cancer-specific express

300 se and cell membrane proteins, including the surface antigen WspA, a peptidoglycan-associated lipopro